Цефодокс

Quick links to important sections

Цефодокс

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Цефодокс

What is Цефодокс?

Цефодокс is the commercial name for the prescription drug Cefpodoxime, a type of antibiotic belonging to the cephalosporin class. Specifically, it is a third-generation cephalosporin.

Mechanism of Action

Cefpodoxime is a prodrug (Cefpodoxime proxetil) that is absorbed from the gastrointestinal tract and converted into its active form, Cefpodoxime. As a bactericidal agent, it works by inhibiting the synthesis of the bacterial cell wall, a vital component for bacterial survival, which results in the death of the bacteria.

Medical Use

Cefpodoxime is used to treat infections caused by susceptible strains of bacteria in various parts of the body. Approved uses include the treatment of bacterial infections such as:

  • Respiratory tract infections, like bronchitis, pneumonia, and certain infections of the sinuses, throat, and tonsils.
  • Skin and skin structure infections.
  • Urinary tract infections (UTIs).
  • Acute otitis media (ear infections).
  • Uncomplicated gonorrhea.

Like all antibiotics, Cefpodoxime is ineffective against viral infections, such as the common cold or flu. It is crucial to use the medication exactly as prescribed for the full duration of treatment, even if symptoms improve quickly, to reduce the risk of developing antibiotic-resistant bacteria.

What side effects are possible with Цефодокс?

Possible side effects and safety information

The safety profile of Cefpodoxime (Цефодокс), a cephalosporin antibiotic, is documented by government regulatory agencies (e.g., FDA and EMA) primarily through the classification of adverse reactions by frequency and affected organ system.

Frequency-Classified Adverse Reactions

The most frequently observed effects are classified as Common (ge 1/100): these primarily involve the Gastrointestinal System and include diarrhea, nausea, vomiting, and abdominal pain, along with headache.

Reactions classified as Uncommon (ge 1/1,000) generally involve the skin, such as pruritus (itching) and urticaria (hives).

Serious Adverse Reactions and Safety Constraints

The official labeling highlights potential serious adverse reactions, though these are rare. These include severe hypersensitivity reactions like Anaphylaxis and Angioedema, as well as life-threatening skin disorders such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Additionally, Cefpodoxime is associated with the risk of Pseudomembranous Colitis and Clostridioides difficile-Associated Diarrhea (CDAD), which can occur even more than two months following treatment.

Population-Specific Considerations

The drug is contraindicated in patients with a documented hypersensitivity to the cephalosporin class of antibiotics. Regulatory documents also specify that individuals with impaired renal function require adjustments due to reduced drug clearance. The use of Cefpodoxime may also result in the overgrowth of non-susceptible organisms (superinfection) and a positive direct Coombs' test.

Overdose and Emergency Response

Overdose involving Cefpodoxime is officially documented to present with initial signs of gastrointestinal distress, including nausea, vomiting, and diarrhea. The most serious toxic manifestations primarily involve the Central Nervous System (CNS), which can lead to encephalopathy (changes in mental status or consciousness) and potentially convulsions (seizures). These severe outcomes are associated with high and prolonged drug concentrations in the body.

Regulatory labeling emphasizes that patients with renal insufficiency or impaired renal function face an increased risk of severe CNS toxicity because reduced drug clearance leads to the accumulation of Cefpodoxime. This documented risk is a critical consideration in overdose scenarios.

For any serious toxic reaction resulting from overdosage, regulatory documents unequivocally mandate that individuals seek immediate medical attention. Management for Cefpodoxime overdose is primarily symptomatic and supportive, since no specific antidote is known. To facilitate drug removal from the systemic circulation in severe cases, medical procedures such as hemodialysis or peritoneal dialysis may be employed. Continuous hospital monitoring is required to manage any developing complications effectively.

Therapeutic Uses of Цефодокс

Cefpodoxime (Цефодокс) may be part of symptomatic management for conditions involving symptoms that interfere with daily functioning due to susceptible bacteria. It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Cefpodoxime is commonly used to help with conditions characterized by symptoms related to physical discomfort in the upper and lower respiratory tract (such as pneumonia, acute bronchitis, and sinusitis), the ear (acute otitis media), uncomplicated urinary tract infections (UTIs), uncomplicated skin infections, and certain forms of uncomplicated gonorrhea.

In clinical settings, the medication may be part of symptomatic management when fever, localized pain, or acute inflammation become difficult to tolerate. It helps address symptom clusters that may become intense or disruptive. This assistance contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability.


Quick Fact: Relief for Acute Discomfort

Quick Fact: The medication is relevant for easing symptoms related to Acute Discomfort in the ear, throat, and sinuses in pediatric and adult patient groups.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Цефодокс (Cefpodoxime)

The population eligibility for Cefpodoxime is strictly defined by regulatory authorities based on allergy history, age, and physiological status.

Absolute Contraindications

Use of the medicine is contraindicated (prohibited) in patients with a history of severe hypersensitivity (allergy) to Cefpodoxime proxetil itself, to any other cephalosporin class antibiotic, or to penicillin class antibiotics.

Age-Related Eligibility

Age Group Eligibility Status
Infants under 2 months of age Safety and efficacy have not been established
Children ge 2 months of age, Adults Use is established
Older Adults No dose adjustment needed unless renal function is impaired

Conditional Use and Restrictions

Patients with moderate to severe renal impairment (low creatinine clearance) require conditional use, meaning the standard daily prescription must be modified (dose reduced or interval increased). Use is generally not recommended for breastfeeding women due to the drug’s excretion into human milk. Caution is advised for individuals with a history of gastrointestinal diseases, particularly colitis, and the oral suspension is restricted for patients with phenylketonuria (PKU) as it contains phenylalanine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents detail several clinically significant interaction patterns for Cefpodoxime. The drug's absorption is highly dependent on gastric acidity, establishing a key interaction domain. Co-administration of gastric pH-elevating agents, such as antacids (e.g., aluminum hydroxide) and H2-receptor antagonists (e.g., cimetidine), significantly reduces the bioavailability of Cefpodoxime, leading to lower plasma concentrations (AUC and Cmax). To mitigate this effect, official regulatory documents require that administration of these agents be separated by at least two to three hours.

Conversely, the co-administration of Probenecid formally inhibits the renal excretion of Cefpodoxime, which results in a documented increase in systemic exposure (AUC and Cmax). The timing of the dose can also be affected by oral anti-cholinergics, which delay the time to peak concentration.

Pharmacodynamic interactions involve augmenting risks with certain drug classes:

  • Nephrotoxic drugs (e.g., potent diuretics) increase the documented risk of kidney damage. Caution is advised, especially in patients with reduced urinary output.
  • Oral anticoagulants may experience an enhanced anticoagulant effect, necessitating frequent monitoring of INR.
  • Oral contraceptives may have their efficacy officially reduced.

The regulatory information also notes that administering Cefpodoxime tablets with food enhances its oral bioavailability. Separately, medicinal products that inhibit peristalsis must be avoided if antibiotic-associated colitis develops.

Mechanism of Action

Irreversible Deactivation of Bacterial Cell Wall Builders

Cefpodoxime's active form functions as a chemical substrate mimic that covalently binds to and inhibits Penicillin-Binding Proteins (PBPs), which are the essential bacterial enzymes (transpeptidases) responsible for completing the rigid peptidoglycan framework of the cell wall. This specific molecular interference halts the necessary cross-linking reactions required to maintain the structural integrity of the microbe.


Bactericidal Lysis via Osmotic Failure

The inhibition of PBP activity triggers a cascading failure: without a properly constructed and maintained cell wall, the bacterial cell loses its ability to counteract its high internal pressure. This deficit in structural integrity leads to an uncontrolled influx of water, causing the microbial cell to rupture (lysis). This physiological collapse ensures a bactericidal effect, representing the physical destruction of the targeted microbe.


Constraint by Enzymatic Inactivation

The drug's mechanism is fundamentally constrained by biological counter-strategies, chiefly the bacterial production of beta-lactamase enzymes. These enzymes chemically degrade and inactivate Cefpodoxime by cleaving its beta-lactam ring before it can reach and inhibit the PBPs. Such enzymatic inactivation prevents the entire cell wall inhibition cascade, thereby circumventing the mechanism of action.

Dosage and Administration Information

Official Administration and Dosing Guidelines

Cefpodoxime (Цефодокс) is an antibiotic prescribed for oral administration. The medicine is typically supplied as film-coated tablets (100 mg or 200 mg) or as granules for oral suspension.

For most approved indications, the standard adult dosing pattern is every 12 hours (twice daily), which is necessary to maintain therapeutic concentrations. The dosage amount, generally between 100 mg and 400 mg, and the total duration of therapy (ranging from 5 to 14 days) are determined by the specific infection treated. For instance, uncomplicated urinary tract infections often require 100 mg every 12 hours for 7 days, while acute exacerbation of chronic bronchitis typically requires 200 mg every 12 hours for 10 days. Uncomplicated gonorrhea is administered as a 200 mg single dose.

Contextual Use Instructions

Dosage Form Required Administration Condition
Tablets Must be administered with food to enhance absorption.
Oral Suspension May be administered without regard to meals.

For the suspension, the granules must be reconstituted with water before use and shaken well before each subsequent dose. The full prescribed course must be completed, even if symptoms begin to resolve earlier.

Population Adjustments

Dosing requires adjustment in patients with impaired renal function. If creatinine clearance is less than 30 mL/ min, the official dosing interval is extended to every 24 hours. No dosage adjustment is necessary for patients with impaired hepatic (liver) function, including cirrhosis, or for older adults who have normal kidney function.

Recent Clinical Evidence

Цефодокс: Overview of Studies


Evidence for Use in Respiratory Tract Infections

Research on Цефодокс has primarily examined its potential role in addressing bacterial infections of the respiratory system, including infections of the ear (acute otitis media), throat (pharyngitis), sinuses (acute sinusitis), and the lungs (pneumonia and bronchitis). Studies, often including Randomized Controlled Trials (RCTs), have been used in research exploring how symptoms change over time. These studies included both adults and children, particularly those with mild to moderate infections evaluated in outpatient settings.

The main outcomes studied were related to two key areas: Clinical response (observed change in acute symptoms like fever and pain) and Bacteriological status (observed change in the susceptible bacteria). Long-term effects are not fully established regarding the findings from these studies, as follow-up durations were typically limited to 28–30 days post-therapy.


Evidence for Use in Urinary Tract Infections (UTIs)

Цефодокс was studied for conditions characterized by acute episodes of uncomplicated Urinary Tract Infections (UTIs), specifically cystitis. Research examined two main outcomes: the observed status of UTI symptoms (clinical status) and the observed status of the susceptible bacteria (bacteriological status).

The evidence landscape includes the limitation that results may be impacted by the factor of antibiotic resistance among uropathogens. Comparative evidence remains limited for more complex or recurring UTIs.


Evidence in Special Populations and Uncertainties

Studies was evaluated in both adults and pediatric groups. However, research for specific other groups, such as the frail older adults with multiple health issues (comorbidities), is constrained. Data for certain groups remain insufficient compared to the general outpatient populations. The research requires continuous re-evaluation as bacterial resistance continually changes.

Key Studies & References

  1. Cefpodoxime: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Цефодокс (FAQ)


Q: Is it normal if Cefpodoxime hasn't helped after two days?

Studies indicate that the concentration of the drug in the blood typically peaks within a few hours of administration. However, the time required to see a noticeable change in symptoms depends on the nature and severity of the specific infection being treated and can take several days.

Official guidance emphasizes the importance of completing the full prescribed course, even if symptoms begin to resolve earlier.


Q: Why can thrush (candidiasis) appear after Cefpodoxime?

Antibiotics, including Cefpodoxime, can cause a disruption in the body's natural balance of microorganisms. This can lead to the overgrowth of non-susceptible organisms, a condition known as a superinfection.

Thrush is a type of superinfection caused by yeast overgrowth that may occur when the antibiotic eliminates the bacteria that normally keep the yeast population in check.


Q: Which form of Cefpodoxime (tablet, suspension) is considered better?

Official regulatory information does not state that one form is inherently better than the other; the choice is based on administration requirements and patient needs. Tablets must be taken with food to ensure proper absorption, while the oral suspension can be taken regardless of meals.

Other factors, such as age and ease of swallowing, typically determine the prescribed formulation.


Q: Does Cefpodoxime kill all bacteria indiscriminately?

No, Cefpodoxime is designed to be active only against specific bacterial strains that are susceptible to it. Like all broad-spectrum antibiotics, it affects the body's normal microbial population, which is why official warnings include the risk of overgrowth of non-susceptible organisms.


Q: What is the probability of developing severe allergic reactions to Cefpodoxime?

According to official regulatory sources, severe allergic reactions, such as anaphylaxis and life-threatening skin disorders, are classified as very rare.

These types of events are documented to affect fewer than 1 in 10,000 people who receive the medication.


Q: Why does Cefpodoxime cause headaches in some people?

Headache is listed in regulatory documents as a common adverse reaction reported during use of Cefpodoxime. While the side effect is well-documented, official patient information does not typically detail the exact mechanism or specific biological cause behind this adverse reaction.


Q: How is Cefpodoxime eliminated from the body?

Official pharmacological data indicates that the active drug, Cefpodoxime, is cleared from the body primarily through the kidneys (renal excretion).

Due to this method of elimination, regulatory documents require that the dosage interval be adjusted for patients who have impaired kidney function.


Q: How long does Cefpodoxime take to start working?

After administration, the drug is quickly absorbed, and the maximum concentration of the active medicine in the bloodstream is typically reached in approximately two to three hours.

This period represents when the drug is most concentrated in the body to begin its therapeutic effect.


Q: Are there official warnings about Cefpodoxime and alcohol?

While the US FDA label may not contain explicit warnings, some international regulatory documents include cautions regarding the consumption of alcohol during treatment.

This caution is based on reports of a potential disulfiram-like reaction, which can cause symptoms such as flushing, headaches, and nausea.


Q: Can Cefpodoxime be taken during pregnancy?

The FDA categorizes Cefpodoxime as Pregnancy Category B. This classification means that animal reproduction studies have not demonstrated a risk to the fetus.

Regulatory guidance describes that the medicine is typically used during pregnancy only when the potential benefit is considered to justify the potential risk.


Q: What should I do if I missed a Cefpodoxime dose?

Official patient guidance describes the procedure for a missed dose: if a dose is missed, it is typically taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely.

Official guidance cautions against taking a double dose to compensate for a missed one.


Q: Can taking Cefpodoxime cause drowsiness?

Yes, regulatory documents list somnolence (drowsiness) as a nervous system-related adverse reaction.

This is a recognized effect that may occur in some individuals using the medication.


Q: Is Cefpodoxime a broad-spectrum or narrow-spectrum antibiotic?

Official classification describes Cefpodoxime as an extended-spectrum or broad-spectrum cephalosporin antibiotic. This indicates that it is effective against a wide variety of susceptible bacterial species, including both Gram-positive and Gram-negative pathogens.


Q: Is it true that Cefpodoxime can affect the liver?

Official warnings note that transient changes in liver function tests (such as increases in enzymes like AST and ALT) have been observed with this class of antibiotics.

However, regulatory information also states that dosage adjustment is not typically required for patients who have existing liver function impairment.


Q: What happens if I accidentally take more Cefpodoxime than needed (Overdose)?

In the event of a suspected overdose, official guidance instructs users to contact a poison control center or emergency services immediately.

Symptoms experienced during accidental overdose often correspond to a severe intensification of common adverse effects, such as gastrointestinal distress.


Q: Are there restrictions on driving a car while taking Cefpodoxime?

Adverse reactions listed in regulatory documents include side effects such as dizziness and somnolence (drowsiness).

Official information states that caution should be exercised when driving or operating machinery, particularly due to the potential for these effects.


Q: Can Cefpodoxime cause a temporary change in taste?

Yes. Official product information lists taste alterations (a change in the ability to taste) among the reported adverse reactions related to the special senses.

In rare cases, this may include a temporary loss of taste.


Q: What does 'broad-spectrum antibiotic' mean for Cefpodoxime?

The term 'broad-spectrum' is used to describe antibiotics that are effective against a wide variety of different types of bacteria, rather than only one specific type.

For Cefpodoxime, this means it is used to treat infections caused by both Gram-positive and Gram-negative species.


Q: How is bacterial sensitivity to Cefpodoxime officially described?

The drug's activity is officially described in regulatory documents by listing the specific susceptible bacterial species it is effective against. This is often supported by data showing the minimum concentration required to inhibit growth (MICs), and it is related to the drug's mechanism of inhibiting the bacterial cell wall synthesis.

How should Цефодокс be stored and disposed of?

How to Store and Dispose of Цефодокс?

The official storage and disposal requirements for Cefpodoxime (Цефодокс) are defined by the product formulation.

Formulation Required Storage Condition Stability Constraint
Tablets Controlled Room Temperature (20°C to 25°C). Keep away from light and excess moisture. N/A
Oral Suspension (Liquid) Refrigerator (2°C to 8°C). Must not be frozen. Discard any unused portion after 14 days.

All forms of the medication must be kept in the original, tightly closed container and placed out of the sight and reach of children. When disposing of expired or unused medicine, do not pour it into a sink or toilet. The required method is using a drug take-back program or mixing the medicine with an unappealing substance, sealing it, and placing it in household trash, per official regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цефодокс found in:

A-Z Index: